BioSpace News Archive

Modifi Biosciences , a leader in DNA modification as a novel approach to target cancer, today announced its Scientific Advisory Board, with the appointments of Joseph Costello, PhD; Vishwas Paralkar, PhD; Manmeet Ahluwalia, MD; Peter Glazer, MD, PhD; Jann Sarkaria, MD; Roger Stupp, MD; Michael Dillon, PhD; and Patricia LoRusso, DO.

Delcath Systems, Inc. announced the closing of the previously announced private placement with certain accredited investors.

NeurOptics’ Neurological Pupil index™ and automated pupillometry are now included in the updated 2021 European Resuscitation Council and European Society of Intensive Care Medicine Guidelines for post-resuscitation care as an objective measurement supporting neurological prognosis in patients following cardiac arrest.

AXIM Biotechnologies, Inc., an international healthcare diagnostic solutions development company, announced that it has filed a provision patent application with the U.S. Patent and Trademark Office on an innovative new rapid ophthalmological diagnostic solution designed to reliably measure both Ocular Immunoglobulin E and MMP-9 in a single test.

Clearmind Medicine Inc. (Nasdaq,CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”) today announced it has completed IND-enabling studies on its CMND-100 (MEAI- based) compound aimed at treating alcohol use disorder (AUD), in preparation for its first in-human clinical trial.

Cyclica Inc. (“Cyclica”), a neo-biotech that is unlocking the protein universe to discover the medicines of tomorrow, and SK Chemicals Co., Ltd. (“SK Chemicals”), a global leader in total healthcare providing diagnostic, therapeutic and prophylactic solutions, today announced an AI-driven drug discovery and development partnership to develop therapies across a range of disease areas.

Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, announced that it has partnered with Gastro Health, a national leading medical group specializing in digestive and liver health, to bring its AI Recruitment technology to Gastro Health’s practices.

Beyond Cancer, Ltd. announced the publication of pre-clinical data demonstrating that its proprietary tumor ablation technology utilizing UNO results in a potent innate and adaptive immune response that prevents metastases and resulted in a statistically significant survival benefit.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives, has hired Chris Twitty, PhD, as the Company’s first chief scientific officer (CSO).

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) today presented the final progression-free survival (PFS) analysis of the ALPINE trial demonstrating superior efficacy and a favorable cardiac safety profile for patients receiving BRUKINSA® as compared to IMBRUVICA® in a global phase 3 trial in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).